Shots:

• The approval is based on P-III DRIVE-FORWARD study assessing Pifeltro (qd) vs darunavir + ritonavir (DRV+r) (800mg- 100 mg- qd) each in combination with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC in patients with HIV-1 infection
• P-III DRIVE-FORWARD study results: @48 wks. viral suppression of HIV-1 RNA <40 copies/mL (83% vs  79%); @96 wks. (72% vs 64%); patients discontinued treatment (2% vs 3%) ; LDL-cholesterol and non-HDL-cholesterol (-4.6--5.4 mg/DL vs 9.5- 13.7 mg/DL)
•  Pifeltro (doravirine- 100mg) is a qd NNRTI in combination with antiretroviral medicines indicated and approved for the HIV-1 infection

Ref: Merck | Image: Merck